Graph Therapeutics

About:

precision-immunology techbio

Website: https://graphtx.com

Top Investors: Merantix Capital, Mehdi Ghissassi

Description:

Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of people are left without adequate treatment options - and AI trained with complex disease data can solve this.